Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Current Opinion in Neurology|November 10, 2007
Incorporating molecular tools into clinical trials and treatment for gliomas?Andrew B Lassman, Eric C Holland
Neurosurgery Clinics of North America|November 25, 2018
Chemotherapy Treatment and Trials in Low-Grade GliomasLaura E Donovan, Andrew B Lassman
Seminars in Radiation Oncology|June 9, 2015
Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Lauren R Schaff, Andrew B Lassman
Neuro-Oncology|October 15, 2016
Biomarkers in NOA-04: another piece to the puzzleAndrew B Lassman, Timothy F Cloughesy
Current Neurology and Neuroscience Reports|April 26, 2006
Unraveling molecular markers of biologic therapies in gliomaAndrew B Lassman, Lauren E Abrey
Nature Clinical Practice. Oncology|January 18, 2007
Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?Andrew B Lassman, Lauren E Abrey
Current Oncology Reports|December 17, 2008
Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directionsDouglas E Ney, Andrew B Lassman
Neuro-Oncology|December 3, 2014
Factorial clinical trials: a new approach to phase II neuro-oncology studiesFabio M Iwamoto, Andrew B Lassman
Neuro-Oncology|February 9, 2021
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?Andrew B Lassman, Timothy F Cloughesy
Neuro-Oncology|April 29, 2017
NovoTTF: where to go from here?Timothy F Cloughesy, Andrew B Lassman
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Current Opinion in Neurology|November 10, 2007
Incorporating molecular tools into clinical trials and treatment for gliomas?Andrew B Lassman, Eric C Holland
Neurosurgery Clinics of North America|November 25, 2018
Chemotherapy Treatment and Trials in Low-Grade GliomasLaura E Donovan, Andrew B Lassman
Seminars in Radiation Oncology|June 9, 2015
Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?Lauren R Schaff, Andrew B Lassman
Neuro-Oncology|October 15, 2016
Biomarkers in NOA-04: another piece to the puzzleAndrew B Lassman, Timothy F Cloughesy
Current Neurology and Neuroscience Reports|April 26, 2006
Unraveling molecular markers of biologic therapies in gliomaAndrew B Lassman, Lauren E Abrey
Nature Clinical Practice. Oncology|January 18, 2007
Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?Andrew B Lassman, Lauren E Abrey
Current Oncology Reports|December 17, 2008
Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directionsDouglas E Ney, Andrew B Lassman
Neuro-Oncology|December 3, 2014
Factorial clinical trials: a new approach to phase II neuro-oncology studiesFabio M Iwamoto, Andrew B Lassman
Neuro-Oncology|February 9, 2021
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?Andrew B Lassman, Timothy F Cloughesy
Neuro-Oncology|April 29, 2017
NovoTTF: where to go from here?Timothy F Cloughesy, Andrew B Lassman
Pageof 15